What is EQUASHIELD?
Founded in 2009, EQUASHIELD operates as a global compounding technology company. Its core mission revolves around safeguarding healthcare professionals from the risks associated with hazardous drug exposure. The company achieves this through the development of advanced automated compounding robots and closed system transfer devices, positioning itself as a critical provider of safety solutions in the healthcare sector. This focus on protection and automation places EQUASHIELD at the intersection of medical technology and worker safety.
How much funding has EQUASHIELD raised?
EQUASHIELD has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
What's next for EQUASHIELD?
The substantial enterprise-level funding, including the recent major strategic investment, signals a pivotal growth phase for EQUASHIELD. This capital is expected to fuel further research and development into next-generation compounding technologies, enhance manufacturing capabilities, and expand its global market reach. The company is poised to solidify its leadership in providing essential safety equipment for handling hazardous drugs, potentially driving significant advancements in hospital pharmacy automation and worker protection protocols.
See full EQUASHIELD company page
